Metabolic analysis of the antidepressive effects of Yangxinshi Tablet in a vascular depression model in mice

Abstract

In recent years, vascular depression has become the focus of international attention. Yangxinshi Tablet (YXST) is usually used in cthe linic for the treatment of arrhythmia and heart failure, but we found that it also has antidepressive effects. The objective of the study was to identify biomarkers related to vascular depression in hippocampus and explore the antidepressive effects of YXST on the mouse model. Untargeted metabolomics based on UHPLC-Q-TOF/MS was applied to identify significantly differential biomarkers between the model group and control group. Unsupervised principal component analysis (PCA) was used to scan the tendency of groups and partial least squares-discriminant analysis (PLS-DA) to distinguish between the vascular depressive mice and the sham. PCA stores showed clear differences in metabolism between the vascular depressive mice and sham groups. The PLS-DA model exhibited 38 metabolites as the biomarkers to distinguish the vascular depressive mice and the sham. Further, YXST significantly regulated 22 metabolites to normal levels. The results suggested that YXST has a comprehensive antidepressive effect on vascular depression via regulation of multiple metabolic pathways including amino acid, the tricarboxylic acid cycle and phosphoglyceride metabolisms. These findings provide insight into the pathophysiological mechanism underlying vascular depression and the mechanism of YXST.

Perturbations in Amino Acid Metabolism in Reserpine-Treated Zebrafish Brain Detected by1H Nuclear Magnetic Resonance-Based Metabolomics

“…54 Histamine is also a neurotransmitter, and disruption of histamine neurotransmission affects behavioral response. 55 In this study, histamine showed the largest fold change (0.7801) among metabolites with a significant t-test ( p = 0.001) between control and stress-like zebrafish brain model. Kano et al reported a significant decrease in histamine H 1 receptor binding in depressed patients and suggested an important role of histaminergic neuro system in pathophysiology of depression.…”

Yangxinshi Tablets Versus Trimetazidine on Exercise Tolerance After Percutaneous Coronary Intervention: Rationale and Design of the Double-blind, Randomized HEARTRIP Trial

“…Suggesting pharmacological pleiotropy, Yangxinshi tablets have been shown to be effective in treating depression/anxiety through both direct mechanisms and indirectly as a consequence of angina relief. [19] In the HEARTRIP trial, we will use the PHQ-9 depression scale and the GAD-7 anxiety screening scale to assess the effects of Yangxinshi tablets on depression and anxiety. The Seattle Angina Questionnaire, a well-established tool to measure patients’ health status, will also be used to evaluate frequency and intensity of angina and quality of life.…”

Effects of Yangxinshi tablet on exercise tolerance in patients with coronary heart disease

“…CR as a multidisciplinary and promising program can also effectively relieve depression and anxiety, thus improve QoL in patients with CHD. [ 34 – 36 ] Previous studies reported the effects of YXS on improving depression-like behaviors, [ 15 ] its role in CR still needs further investigation. The safety of the YXS tablet will be evaluated as patients’ symptoms and laboratory tests, such as blood routine, urine routine, liver and renal function, and echocardiography.…”

“…It has been widely used for the treatment of CHD, relieving symptoms of angina pectoris, and protecting myocardial ischemia. [ 15 ] A previous study has already reported the effects of promoting rehabilitation after the percutaneous coronary intervention with no obvious side effect, [ 16 ] whether it could help improve EC for patients with CHD is still unclear. Our study aims to investigate the efficacy and safety of YXS tablet on the exercise tolerance in CHD and its role in the CR program.…”